FDA
-
-
-
-
-
-
-
Novartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)
-
328,602 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

